CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

October 18, 2018

Study Completion Date

October 18, 2018

Conditions
Hepatocellular Carcinoma
Interventions
GENETIC

CAR-GPC3 T cells

"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."

Trial Locations (1)

20001

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

RenJi Hospital

OTHER